Founder and Principal Consultant at 1st Line Partners.

Articles

Counterfeit pharma networks are becoming more sophisticated—leveraging advanced packaging, fragmented logistics, and global trade gaps—making detection harder and patient risk greater than ever.

A 'Beautiful Fake': Pharma Fraudsters Upping Their Game 

Rising prescription costs and premiums are forcing more than half of patients to take drastic measures to cover OOP costs.

Americans Call on Policymakers to Prioritize Healthcare Access and Affordability

Various agreements with the Trump administration could have long-term ramifications for Medicaid access and global pricing strategy.

The Longer-Term Impact of MFN Pricing

. He can be reached at nsaraceno@mjhlifesciences.com.

As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC.

Trade & Channel Strategies 2025: DSCSA Status Following Implementation

A founding partner with Curatio Scientia Advisors.

Videos

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access services with traditional distribution models is setting the stage for medically integrated dispensing to expand beyond oncology.

Trade & Channel Strategies 2025: Trade and Channel Strategies in the Era of Medically Integrated Dispensing

Podcasts

In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.

Pharma Pulse: FDA Fast-Tracks Antibiotic Approval, as Protected EHR Time Combats Physician Burnout

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, highlights how two decades of commercial trade and distribution have transformed the channel from a primarily supply-chain-focused function into a more integrated discipline.

Trade & Channel Strategies 2025: Channel Evolution Over the Last 20 Years

Subject matter experts from Cencora and FuzeRx explore how modern commercialization models, digital-first pharmacy solutions, and closer provider partnerships are reshaping patient access and adherence across today’s complex therapeutic landscape.

Trade & Channel Strategies 2025: Channel Strategies Evolve, With Industry Leaders Pushing Toward Faster, More Connected Patient Access

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.

Pharma Pulse: FDA Shifts CAR-T Standards and Maryland Expands Medical Class Size, as Pharma Channels Brace for Massive Patent Cliff Disruption

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

News